RT Journal Article
SR Electronic
T1 Leveraging serology testing to identify children at risk for post-acute sequelae of SARS-CoV-2 infection: An EHR-based cohort study from the RECOVER program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.20.22276645
DO 10.1101/2022.06.20.22276645
A1 Mejias, Asuncion
A1 Schuchard, Julia
A1 Rao, Suchitra
A1 Bennett, Tellen D.
A1 Jhaveri, Ravi
A1 Thacker, Deepika
A1 Bailey, L. Charles
A1 Christakis, Dimitri A.
A1 Pajor, Nathan M.
A1 Razzaghi, Hanieh
A1 Forrest, Christopher B.
A1 Lee, Grace M.
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/06/22/2022.06.20.22276645.abstract
AB The impact of post-acute sequelae of SARS-CoV-2 infection (PASC) in children is underrecognized. We developed an EHR-based algorithm across eight pediatric institutions to identify children with COVID-19 based on serology testing from 3/2020 through 4/2022 who had not been identified by PCR. Overall, serology tests were used 100-fold less than PCR. Seroprevalence of IgG anti-nucleocapsid antibodies remained stable, while rates of positive IgG anti-spike antibodies increased in teenagers after COVID-19 vaccine approval. Through data harmonization and after excluding 1,410 serology test results that may have been influenced by vaccines, we identified 2,714 children that were COVID-19 positive exclusively by serology. These patients were frequently tested as inpatients (24% vs. 2%), had chronic conditions more frequently (37% vs 24%), and a MIS-C diagnosis (23% vs. <1%) compared with PCR-positive children. Identification of children that could have been paucisymptomatic, not tested, or missed is critical to define the burden of PASC in children.Competing Interest StatementAsuncion Mejias reports funding from Janssen, Merck for research support, and Janssen, Merck and Sanofi-Pasteur for Advisory Board participation; SR reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Ravi Jhaveri is a consultant for AstraZeneca, Seqirus and Dynavax, and receives an editorial stipend from Elsevier.Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01 as part of the Researching COVID to Enhance Recovery (RECOVER) program of research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Childrens Hospital of Philadelphia Institutional Review Board designated this study as not human subjects research and waived informed consentI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon reasonable request to the authorsCOVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2EHRelectronic health recordEDemergency departmentNnucleocapsidSspikeRBDreceptor binding domainPCRpolymerase chain reactionPASCpost-acute sequelae of SARS-CoV-2 infectionMIS-Cmultisystem inflammatory syndrome in childrenFDAFood and Drug Administration--FDACDCCenter for Diseases Control and Prevention